Expert Interview
Discussing the results of Edwards Lifesciences EARLY-TAVR trial for Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis patients
Ticker(s): EW, MDT, ABTInstitution: North Shore Heart and Vascular
- Interventional Cardiologist
- Manages treatment for 50 patients with Hypertrophic Cardiomyopathy and places 10-15 aoritc heart valves a month
- Clinical interest in nuclear cardiology
Describe your background and practice setting
Added By: ben_adminHow many TAVR procedures do you conduct yearly?
Added By: ben_adminWhich TAVR platforms do you currently utilize in your setting?
Added By: ben_adminWhat are your thoughts on the results from the EARLY-TAVR trial?
Added By: ben_adminWhat are the key differences between valve systems like SAPIEN and CoreValve, and how do these affect patient outcomes and procedural choices?
Added By: slingshot_insightsHow durable are TAVR valves compared to surgical ones, and what follow-up protocol do you recommend for asymptomatic patients?
Added By: slingshot_insightsWhat are your thoughts on the EARLY-TAVR trial's findings for asymptomatic patients, and how might it impact timing and decision-making for interventions?
Added By: slingshot_insightsDo you foresee changes in procedural volumes or valve preferences based on this trial, and how might newer technologies like Abbott's or Boston Scientific's valves impact the market?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
